よむ、つかう、まなぶ。
07 参考資料 1－1 百日せきファクトシート［6.8MB］ (45 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_34803.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第20回 8／29）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
115. 高山直秀，菅沼明彦. 成人へのジフテリア・百日咳・破傷風 3 種混合ワクチン接
種調査．Progress in Medicine. 2007. 27: 1699-702.
116. 柳澤如樹、高山直秀、菅沼明彦. 成人におけるジフテリア・百日咳・破傷風（DPT）
3 種混合ワクチン 0.2mL 接種の百日咳抗体への効果. 日本感染症学雑誌. 2009.
83：7-11.
117. Okada K, Komiya T, Yamamoto A, Takahashi M, Kamachi K, Nakano T, Nagai T, Okabe
N,Kamiya H,Nakayama T. Safe and effective booster immunization using DTaP in
teenagers. Vaccine. 2010. 28:7626-33.
118. Hara M, Okada K, Yamaguchi Y, Uno S, Otsuka Y, Shimanoe C, Nanri H, Horita M, Ozaki
I, Nishida Y, Tanaka K. Immunogenicity and safety after booster vaccination of diphtheria,
tetanus, and acellular pertussis in young adults: an open randomized controlled trial in
Japan. Clin Vaccine Immunol. 2013. 20:1799-804.
119. 独立行政法人医薬品医療機器総合機構：審査結果報告書.
テ リア破傷風混合ワクチン「トリビック®」平成
28
年
沈降精製百日せきジフ
2
月
24
日http://
www.pmda.go.jp/drugs/2015/P20160307001/630144000_21800AMZ10361_A100_1
.pdf
120. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, Mijalski CM,
Tiwari T, Weston EJ, Cohn AC, Srivastava PU, Moran JS, Schwartz B, Murphy TV,
Advisory Committee on Immunization P. Preventing tetanus, diphtheria, and pertussis
among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR. 2006. 55:1-34.
121. Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children,
adolescents and adults. Drugs. 2005. 65:1367-89.
122. Liese JG, Stojanov S, Zink TH, Froeschle J. Safety and immunogenicity of Biken acellular
pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to
six years of age. Pediatr Infect Dis J. 2001. 10:981-8.
123. Schmitt HJ, Mohnike K, Zepp F, Herden P, Hosbach P. Immunogenicity and reactogenicity
of the Biken acellular pertussis vaccine in young adults. Vaccine. 2000. 19:403-8.
124. Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE,
Blackwelder WC, Jansen DL, Meade BD. Safety and immunogenicity of six acellular
pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to
six-year-old children. Pediatrics. 2000. 105:e11.
125. Keitel WA, Muenz LR, Decker MD, Englund JA, Mink CM, Blumberg DA, Edwards KM.
A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response
comparisons of 5 vaccines and implications for booster immunization. J Infect Dis. 1999.
44
種調査．Progress in Medicine. 2007. 27: 1699-702.
116. 柳澤如樹、高山直秀、菅沼明彦. 成人におけるジフテリア・百日咳・破傷風（DPT）
3 種混合ワクチン 0.2mL 接種の百日咳抗体への効果. 日本感染症学雑誌. 2009.
83：7-11.
117. Okada K, Komiya T, Yamamoto A, Takahashi M, Kamachi K, Nakano T, Nagai T, Okabe
N,Kamiya H,Nakayama T. Safe and effective booster immunization using DTaP in
teenagers. Vaccine. 2010. 28:7626-33.
118. Hara M, Okada K, Yamaguchi Y, Uno S, Otsuka Y, Shimanoe C, Nanri H, Horita M, Ozaki
I, Nishida Y, Tanaka K. Immunogenicity and safety after booster vaccination of diphtheria,
tetanus, and acellular pertussis in young adults: an open randomized controlled trial in
Japan. Clin Vaccine Immunol. 2013. 20:1799-804.
119. 独立行政法人医薬品医療機器総合機構：審査結果報告書.
テ リア破傷風混合ワクチン「トリビック®」平成
28
年
沈降精製百日せきジフ
2
月
24
日http://
www.pmda.go.jp/drugs/2015/P20160307001/630144000_21800AMZ10361_A100_1
120. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, Mijalski CM,
Tiwari T, Weston EJ, Cohn AC, Srivastava PU, Moran JS, Schwartz B, Murphy TV,
Advisory Committee on Immunization P. Preventing tetanus, diphtheria, and pertussis
among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR. 2006. 55:1-34.
121. Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children,
adolescents and adults. Drugs. 2005. 65:1367-89.
122. Liese JG, Stojanov S, Zink TH, Froeschle J. Safety and immunogenicity of Biken acellular
pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to
six years of age. Pediatr Infect Dis J. 2001. 10:981-8.
123. Schmitt HJ, Mohnike K, Zepp F, Herden P, Hosbach P. Immunogenicity and reactogenicity
of the Biken acellular pertussis vaccine in young adults. Vaccine. 2000. 19:403-8.
124. Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE,
Blackwelder WC, Jansen DL, Meade BD. Safety and immunogenicity of six acellular
pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to
six-year-old children. Pediatrics. 2000. 105:e11.
125. Keitel WA, Muenz LR, Decker MD, Englund JA, Mink CM, Blumberg DA, Edwards KM.
A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response
comparisons of 5 vaccines and implications for booster immunization. J Infect Dis. 1999.
44